Article: An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleAn M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses
AuthorsZhao, G1 2
Lin, Y2
Du, L3
Guan, J1
Sun, S1
Sui, H2
Kou, Z1
Chan, CC2
Guo, Y1
Jiang, S3
Zheng, BJ2
Zhou, Y1
Issue Date2010
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.virologyj.com/home/
CitationVirology Journal, 2010, v. 7 [How to Cite?]
DOI: http://dx.doi.org/10.1186/1743-422X-7-9
AbstractBackground. A growing concern has raised regarding the pandemic potential of the highly pathogenic avian influenza (HPAI) H5N1 viruses. Consequently, there is an urgent need to develop an effective and safe vaccine against the divergent H5N1 influenza viruses. In the present study, we designed a tetra-branched multiple antigenic peptide (MAP)-based vaccine, designated M2e-MAP, which contains the sequence overlapping the highly conserved extracellular domain of matrix protein 2 (M2e) of a HPAI H5N1 virus, and investigated its immune responses and cross-protection against different clades of H5N1 viruses. Results. Our results showed that M2e-MAP vaccine induced strong M2e-specific IgG antibody responses following 3-dose immunization of mice with M2e-MAP in the presence of Freunds' or aluminium (alum) adjuvant. M2e-MAP vaccination limited viral replication and attenuated histopathological damage in the challenged mouse lungs. The M2e-MAP-based vaccine protected immunized mice against both clade1: VN/1194 and clade2.3.4: SZ/406H H5N1 virus challenge, being able to counteract weight lost and elevate survival rate following lethal challenge of H5N1 viruses. Conclusions. These results suggest that M2e-MAP presenting M2e of H5N1 virus has a great potential to be developed into an effective subunit vaccine for the prevention of infection by a broad spectrum of HPAI H5N1 viruses. © 2010 Zhao et al; licensee BioMed Central Ltd.
ISSN1743-422X
2011 Impact Factor: 2.343
2011 SCImago Journal Rankings: 0.216
DOIhttp://dx.doi.org/10.1186/1743-422X-7-9
ISI Accession Number IDWOS:000275091300001
Funding AgencyGrant Number
National High Technology R&D Program of China2006AA02Z406
National Basic Research Program of China2005CB523001
National Natural Science Foundation of China30901371
Mega-projects of Science Research2009ZX10004-4001
University Grants CommitteeAoE/M-12/06
Research Fund for the Control of Infectious Diseases, Hong Kong SAR09080812
Funding Information:

This study was supported by the National High Technology R&D Program of China (863 Program, No. 2006AA02Z406), National Basic Research Program of China (973 Program, No. 2005CB523001), National Natural Science Foundation of China (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-4001), the Area of Excellence Scheme of the University Grants Committee (Grant AoE/M-12/06) and Research Fund for the Control of Infectious Diseases (09080812), Hong Kong SAR.

PubMed Central IDPMC2823673
ReferencesReferences in Scopus
GrantsCross-protective efficacy of immunization with different forms of M2 vaccines and their combinations with HA vaccines against highly pathogenic H5N1 influenza A viruses in mice
Control of Pandemic and Inter-pandemic Influenza
DC Field
Value
dc.contributor.authorZhao, G
dc.contributor.authorLin, Y
dc.contributor.authorDu, L
dc.contributor.authorGuan, J
dc.contributor.authorSun, S
dc.contributor.authorSui, H
dc.contributor.authorKou, Z
dc.contributor.authorChan, CC
dc.contributor.authorGuo, Y
dc.contributor.authorJiang, S
dc.contributor.authorZheng, BJ
dc.contributor.authorZhou, Y
dc.date.accessioned2010-10-31T11:13:09Z
dc.date.available2010-10-31T11:13:09Z
dc.date.issued2010
dc.description.abstractBackground. A growing concern has raised regarding the pandemic potential of the highly pathogenic avian influenza (HPAI) H5N1 viruses. Consequently, there is an urgent need to develop an effective and safe vaccine against the divergent H5N1 influenza viruses. In the present study, we designed a tetra-branched multiple antigenic peptide (MAP)-based vaccine, designated M2e-MAP, which contains the sequence overlapping the highly conserved extracellular domain of matrix protein 2 (M2e) of a HPAI H5N1 virus, and investigated its immune responses and cross-protection against different clades of H5N1 viruses. Results. Our results showed that M2e-MAP vaccine induced strong M2e-specific IgG antibody responses following 3-dose immunization of mice with M2e-MAP in the presence of Freunds' or aluminium (alum) adjuvant. M2e-MAP vaccination limited viral replication and attenuated histopathological damage in the challenged mouse lungs. The M2e-MAP-based vaccine protected immunized mice against both clade1: VN/1194 and clade2.3.4: SZ/406H H5N1 virus challenge, being able to counteract weight lost and elevate survival rate following lethal challenge of H5N1 viruses. Conclusions. These results suggest that M2e-MAP presenting M2e of H5N1 virus has a great potential to be developed into an effective subunit vaccine for the prevention of infection by a broad spectrum of HPAI H5N1 viruses. © 2010 Zhao et al; licensee BioMed Central Ltd.
dc.description.grantCross-protective efficacy of immunization with different forms of M2 vaccines and their combinations with HA vaccines against highly pathogenic H5N1 influenza A viruses in mice
dc.description.grantControl of Pandemic and Inter-pandemic Influenza
dc.description.grantcode101167
dc.description.grantcode97655
dc.description.naturepublished_or_final_version
dc.identifier.citationVirology Journal, 2010, v. 7 [How to Cite?]
DOI: http://dx.doi.org/10.1186/1743-422X-7-9
dc.identifier.citeulike6564277
dc.identifier.doihttp://dx.doi.org/10.1186/1743-422X-7-9
dc.identifier.hkuros175099
dc.identifier.isiWOS:000275091300001
Funding AgencyGrant Number
National High Technology R&D Program of China2006AA02Z406
National Basic Research Program of China2005CB523001
National Natural Science Foundation of China30901371
Mega-projects of Science Research2009ZX10004-4001
University Grants CommitteeAoE/M-12/06
Research Fund for the Control of Infectious Diseases, Hong Kong SAR09080812
Funding Information:

This study was supported by the National High Technology R&D Program of China (863 Program, No. 2006AA02Z406), National Basic Research Program of China (973 Program, No. 2005CB523001), National Natural Science Foundation of China (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-4001), the Area of Excellence Scheme of the University Grants Committee (Grant AoE/M-12/06) and Research Fund for the Control of Infectious Diseases (09080812), Hong Kong SAR.

dc.identifier.issn1743-422X
2011 Impact Factor: 2.343
2011 SCImago Journal Rankings: 0.216
dc.identifier.issuearticle no. 9
dc.identifier.openurl
dc.identifier.pmcidPMC2823673
dc.identifier.pmid20082709
dc.identifier.scopuseid_2-s2.0-77249104563
dc.identifier.urihttp://hdl.handle.net/10722/125131
dc.identifier.volume7
dc.languageeng
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.virologyj.com/home/
dc.publisher.placeUnited Kingdom
dc.relation.ispartofVirology Journal
dc.relation.referencesReferences in Scopus
dc.rightsVirology Journal. Copyright © BioMed Central Ltd.
dc.subject.meshAdjuvants, Immunologic - administration and dosage
dc.subject.meshAntigens, Viral - immunology
dc.subject.meshInfluenza A Virus, H5N1 Subtype - immunology
dc.subject.meshInfluenza Vaccines - immunology
dc.subject.meshViral Matrix Proteins - immunology
dc.titleAn M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses
dc.typeArticle
Author Affiliations
  1. Institute of Microbiology Chinese Academy of Sciences
  2. The University of Hong Kong
  3. New York Blood Center